Beida Pharmaceutical said that after years of efforts and a series of clinical trials, the company provided clinicians with sufficient evidence-based medical evidence on the efficacy and safety of patients with non-small cell lung cancer (NSCLC), and the differentiated advantages of ectinib continued to accumulate, which won a good reputation in the targeted drug market of NSCLC and established the brand image of domestic innovative drugs, thus laying the foundation for the sustained growth of sales. ?
Well-known biotechnology company Jiakesi Pharmaceutical submitted an IPO application on the Hong Kong Stock Exchange, and the co-sponsors were Goldman Sachs and CICC. This is a clinical biotechnology company dedicated to providing patients with breakthrough treatment programs. The rapid drug development project includes two clinical stages (JAB-3068 and JAB-33 12) of allosteric protein tyrosine phosphatase (SHP2) inhibitors. According to the preliminary prospectus, about 88.0% of the funds raised by Hong Kong IPO will be used for clinical research and development and commercialization of key products under research.
As a national high-tech enterprise founded by Dr. Haigui's team, which focuses on the research and development of innovative drugs with independent intellectual property rights and integrates pharmaceutical R&D, production and marketing, Beida Pharmaceutical landed in A shares as early as 20 16 1 1, and its product line covers many diseases such as cancer. At present, there are more than 30 products under research, and 13 has entered clinical research. In order to help investors participate in the innovation of Hong Kong stocks, Aide Securities and Futures also launched a heavy activity of Aide's new users, which has rich benefits in account opening, fund deposit and innovation. ?